The Long Road from Discovery to Design
Brian Topp, Senior Director, Merck, Rahway, NJ
Feb 21, 2024 12:00-1:00 PM EST
Registration is free: https://rosaandco.com/webinars
Abstract: Lockheed Martin does not discovery fighter jets. Ferrari dose not
discover F1 race cars. Increasingly, the pharmaceutical industry does not
discover drugs. Novel therapies are engineered. Target selection is dependent
on reverse engineering of complex physiologic systems. Molecules are designed
to display desired characteristics via knowledge of 3D structural chemistry.
Patient selection, trial design, and combination therapies are increasingly
dependent on causal (physiologic-based) mathematical models. Today I will
provide some insights gained during my 20 years as a systems modeler then
describe some recent finding from our systems oncology group focusing on
lesion-to-lesion heterogeneity in patients with advanced cancer.